Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,gmtOffSetMilliseconds,esgPopulated,tradeable,currency,marketState,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,exchange,priceHint,market,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Aug 12, 2021) 4","Short Ratio (Aug 12, 2021) 4","Short % of Float (Aug 12, 2021) 4","Short % of Shares Outstanding (Aug 12, 2021) 4","Shares Short (prior month Jul 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,DTIL,99210000,57480300,37235000,,21656000,,21656000,9938000,68805000,21632000,21632000,,-24000,,,,0,68805000,47173000,0,24000,,21656000,21656000,1343000,384611000,129561000,100553000,23830000,230114000,5416000,-283106000,85788000,-952000,1865000,173943000,36251000,38602000,188304000,488000,478000,-76844000,-1690000,2470000,13512000,-1505000,11055000,-19517000,-31339000,2664000,18775000,-13000,3915000,-1690000,152053000,en-US,US,EQUITY,True,Nasdaq Real Time Price,10.222752,12.56 - 13.86,12.57,13.52,13.58,18,9,finmb_41018856,NasdaqGS,"Precision BioSciences, Inc.",USD,558470,415833,9.4,2.1099887,4.455 - 16.6,-2.7450008,-0.1653615,4.455,16.6,1620889201,1628685000,1629117000,-14400000,False,False,USD,REGULAR,-1.89,-2.24,-1.17,-11.841881,1.028,10.346945,3.5080547,0.33904257,10.472826,3.3821735,0.32294756,796389504,-6.1852674,13.477626,15,America/New_York,EDT,"Precision BioSciences, Inc.",13.855,1630506250,1.2849998,12.65,13.86,12.56,307492,0,NMS,2,us_market,1.67,,,16.6,4.45,10.35,10.47,558.47k,415.83k,57.48M,,49.47M,11.07%,56.39%,2.95M,8.45,5.54%,4.95%,2.88M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",-45.88%,-46.01%,-14.07%,-49.96%,101.36M,1.85,"6,282.70%",24.29M,-37.67M,-46.5M,-1.89,,173.94M,2.92,12.01M,11.95,5.19,1.03,1.06M,-13.53M,Value,27701,Healthcare,236,8,4,"Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic anti-CD19 CAR T cell product candidate for the patients with relapsed or refractory, or R/R, non-Hodgkin lymphoma, or NHL, or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; and PBCAR20A, that is in Phase 1/2a clinical trial, an allogeneic anti-CD20 CAR T therapy for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, which is in Phase 1/2a clinical trial, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R/R multiple myeloma. The Food segment develops food and nutrition products; and provides technology-centric solutions, Elo life systems, and Elo's technology platform solutions. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.",Durham,919 314 5512,NC,8,1609372800,1625097600,9,United States,http://www.precisionbiosciences.com,86400,8,302 East Pettigrew Street,480 393 5553,Biotechnology,Suite A-100
t-1,DTIL,57464000,57480300,25593000,,-18689000,,-18689000,9498000,16349000,-18742000,-18742000,,-24000,,,,0,16349000,35091000,0,53000,,-18689000,-18689000,1358000,364536000,203494000,58822000,55124000,262316000,35000,-304762000,131635000,-952000,1812000,193460000,63797000,40007000,219139000,19263000,445000,93135000,-1125000,2470000,36715000,-3232000,36715000,103662000,68072000,2466000,-9263000,-13000,3655000,-1125000,155342000,en-US,US,EQUITY,True,Nasdaq Real Time Price,10.222752,12.56 - 13.86,12.57,13.52,13.58,18,9,finmb_41018856,NasdaqGS,"Precision BioSciences, Inc.",USD,558470,415833,9.4,2.1099887,4.455 - 16.6,-2.7450008,-0.1653615,4.455,16.6,1620889201,1628685000,1629117000,-14400000,False,False,USD,REGULAR,-1.89,-2.24,-1.17,-11.841881,1.028,10.346945,3.5080547,0.33904257,10.472826,3.3821735,0.32294756,796389504,-6.1852674,13.477626,15,America/New_York,EDT,"Precision BioSciences, Inc.",13.855,1630506250,1.2849998,12.65,13.86,12.56,307492,0,NMS,2,us_market,1.67,,,16.6,4.45,10.35,10.47,558.47k,415.83k,57.48M,,49.47M,11.07%,56.39%,2.95M,8.45,5.54%,4.95%,2.88M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",-45.88%,-46.01%,-14.07%,-49.96%,101.36M,1.85,"6,282.70%",24.29M,-37.67M,-46.5M,-1.89,,173.94M,2.92,12.01M,11.95,5.19,1.03,1.06M,-13.53M,Value,27701,Healthcare,236,8,4,"Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic anti-CD19 CAR T cell product candidate for the patients with relapsed or refractory, or R/R, non-Hodgkin lymphoma, or NHL, or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; and PBCAR20A, that is in Phase 1/2a clinical trial, an allogeneic anti-CD20 CAR T therapy for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, which is in Phase 1/2a clinical trial, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R/R multiple myeloma. The Food segment develops food and nutrition products; and provides technology-centric solutions, Elo life systems, and Elo's technology platform solutions. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.",Durham,919 314 5512,NC,8,1609372800,1625097600,9,United States,http://www.precisionbiosciences.com,86400,8,302 East Pettigrew Street,480 393 5553,Biotechnology,Suite A-100
t-2,DTIL,43052000,57480300,19772000,,-23453000,,-23453000,12554000,8846000,-23480000,-23480000,,-24000,,,,0,8846000,32326000,0,27000,,-23453000,-23453000,1373000,331450000,105733000,44425000,31090000,150158000,4000,-286073000,54318000,-952000,1721000,89798000,42829000,41500000,105564000,10000000,792000,1036000,-1096000,2470000,198000,2489000,198000,-14350000,-13452000,2471000,116000,-13000,3889000,-1096000,62735000,en-US,US,EQUITY,True,Nasdaq Real Time Price,10.222752,12.56 - 13.86,12.57,13.52,13.58,18,9,finmb_41018856,NasdaqGS,"Precision BioSciences, Inc.",USD,558470,415833,9.4,2.1099887,4.455 - 16.6,-2.7450008,-0.1653615,4.455,16.6,1620889201,1628685000,1629117000,-14400000,False,False,USD,REGULAR,-1.89,-2.24,-1.17,-11.841881,1.028,10.346945,3.5080547,0.33904257,10.472826,3.3821735,0.32294756,796389504,-6.1852674,13.477626,15,America/New_York,EDT,"Precision BioSciences, Inc.",13.855,1630506250,1.2849998,12.65,13.86,12.56,307492,0,NMS,2,us_market,1.67,,,16.6,4.45,10.35,10.47,558.47k,415.83k,57.48M,,49.47M,11.07%,56.39%,2.95M,8.45,5.54%,4.95%,2.88M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",-45.88%,-46.01%,-14.07%,-49.96%,101.36M,1.85,"6,282.70%",24.29M,-37.67M,-46.5M,-1.89,,173.94M,2.92,12.01M,11.95,5.19,1.03,1.06M,-13.53M,Value,27701,Healthcare,236,8,4,"Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic anti-CD19 CAR T cell product candidate for the patients with relapsed or refractory, or R/R, non-Hodgkin lymphoma, or NHL, or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; and PBCAR20A, that is in Phase 1/2a clinical trial, an allogeneic anti-CD20 CAR T therapy for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, which is in Phase 1/2a clinical trial, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R/R multiple myeloma. The Food segment develops food and nutrition products; and provides technology-centric solutions, Elo life systems, and Elo's technology platform solutions. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.",Durham,919 314 5512,NC,8,1609372800,1625097600,9,United States,http://www.precisionbiosciences.com,86400,8,302 East Pettigrew Street,480 393 5553,Biotechnology,Suite A-100
t-3,DTIL,62437000,57480300,24873000,,-26016000,,-26016000,8534000,7363000,-26044000,-26044000,,-24000,,,,0,7363000,33407000,0,28000,,-26016000,-26016000,1387000,327396000,104863000,63824000,29219000,168687000,61000,-262620000,53789000,-952000,1555000,104148000,41983000,43185000,122560000,10116000,959000,3571000,-1047000,2470000,532000,4047000,532000,-22738000,-22223000,2499000,-10033000,-13000,3709000,-1047000,80577000,en-US,US,EQUITY,True,Nasdaq Real Time Price,10.222752,12.56 - 13.86,12.57,13.52,13.58,18,9,finmb_41018856,NasdaqGS,"Precision BioSciences, Inc.",USD,558470,415833,9.4,2.1099887,4.455 - 16.6,-2.7450008,-0.1653615,4.455,16.6,1620889201,1628685000,1629117000,-14400000,False,False,USD,REGULAR,-1.89,-2.24,-1.17,-11.841881,1.028,10.346945,3.5080547,0.33904257,10.472826,3.3821735,0.32294756,796389504,-6.1852674,13.477626,15,America/New_York,EDT,"Precision BioSciences, Inc.",13.855,1630506250,1.2849998,12.65,13.86,12.56,307492,0,NMS,2,us_market,1.67,,,16.6,4.45,10.35,10.47,558.47k,415.83k,57.48M,,49.47M,11.07%,56.39%,2.95M,8.45,5.54%,4.95%,2.88M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",-45.88%,-46.01%,-14.07%,-49.96%,101.36M,1.85,"6,282.70%",24.29M,-37.67M,-46.5M,-1.89,,173.94M,2.92,12.01M,11.95,5.19,1.03,1.06M,-13.53M,Value,27701,Healthcare,236,8,4,"Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic anti-CD19 CAR T cell product candidate for the patients with relapsed or refractory, or R/R, non-Hodgkin lymphoma, or NHL, or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; and PBCAR20A, that is in Phase 1/2a clinical trial, an allogeneic anti-CD20 CAR T therapy for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, which is in Phase 1/2a clinical trial, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R/R multiple myeloma. The Food segment develops food and nutrition products; and provides technology-centric solutions, Elo life systems, and Elo's technology platform solutions. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.",Durham,919 314 5512,NC,8,1609372800,1625097600,9,United States,http://www.precisionbiosciences.com,86400,8,302 East Pettigrew Street,480 393 5553,Biotechnology,Suite A-100
